Biomarkers in drug development: guidance, assays and validation with Robert Nelson

In this Expert Perspective, Robert Nelson, Covance (Geneva, Switzerland) discusses the importance of biomarkers in drug development, describing key aspects in the current guidance and the key considerations that should be made in the development and validation process.

About the author:

Robert Nelson is the Associate Director of Science and Innovation at Covance, For over 10 years, he has worked in regulated (GLP/GCP) laboratory environments, supporting preclinical and clinical drug development programs, with contrasting experiences in the immunoassay groups of a large full-service contract research organisation and a medium-sized biotech company.

Original publication:

Video originally published on Bioanalysis Zone, a digital platform from the Future Science Group that aims to advance the field of bioanalysis by increasing subject understanding and sharing of knowledge across barriers to unite the bioanalytical community.